Analysts Are Updating Their BridgeBio Pharma, Inc. (NASDAQ:BBIO) Estimates After Its First-Quarter Results

BridgeBio Pharma, Inc. (NASDAQ:BBIO) shareholders are probably feeling a little disappointed, since its shares fell 2.3% to US$67.39 in the week after its latest quarterly results. The results don't look great, especially considering that statutory losses grew 24% toUS$0.84 per share. Revenues of US$195m did beat expectations by 8.9%, but it looks like a bit of a cold comfort. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. So we gathered the latest post-earnings forecasts to see what estimates suggest is in store for next year.

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.NasdaqGS:BBIO Earnings and Revenue Growth May 11th 2026

After the latest results, the 19 analysts covering BridgeBio Pharma are now predicting revenues of US$951.3m in 2026. If met, this would reflect a major 64% improvement in revenue compared to the last 12 months. The loss per share is expected to greatly reduce in the near future, narrowing 40% to US$2.19. Before this earnings announcement, the analysts had been modelling revenues of US$913.1m and losses of US$1.94 per share in 2026. So it's pretty clear the analysts have mixed opinions on BridgeBio Pharma even after this update; although they upped their revenue numbers, it came at the cost of a notable increase in per-share losses.

View our latest analysis for BridgeBio Pharma

The consensus price target stayed unchanged at US$102, seeming to suggest that higher forecast losses are not expected to have a long term impact on the valuation. That's not the only conclusion we can draw from this data however, as some investors also like to consider the spread in estimates when evaluating analyst price targets. Currently, the most bullish analyst values BridgeBio Pharma at US$157 per share, while the most bearish prices it at US$80.00. Note the wide gap in analyst price targets? This implies to us that there is a fairly broad range of possible scenarios for the underlying business.

Taking a look at the bigger picture now, one of the ways we can understand these forecasts is to see how they compare to both past performance and industry growth estimates. It's clear from the latest estimates that BridgeBio Pharma's rate of growth is expected to accelerate meaningfully, with the forecast 93% annualised revenue growth to the end of 2026 noticeably faster than its historical growth of 51% p.a. over the past five years. Compare this with other companies in the same industry, which are forecast to grow their revenue 22% annually. It seems obvious that, while the growth outlook is brighter than the recent past, the analysts also expect BridgeBio Pharma to grow faster than the wider industry.

Story Continues

The Bottom Line

The most important thing to take away is that the analysts increased their loss per share estimates for next year. Happily, they also upgraded their revenue estimates, and are forecasting them to grow faster than the wider industry. The consensus price target held steady at US$102, with the latest estimates not enough to have an impact on their price targets.

With that in mind, we wouldn't be too quick to come to a conclusion on BridgeBio Pharma. Long-term earnings power is much more important than next year's profits. We have estimates - from multiple BridgeBio Pharma analysts - going out to 2028, and you can see them free on our platform here.

Don't forget that there may still be risks. For instance, we've identified 1 warning sign for BridgeBio Pharma that you should be aware of.

Have feedback on this article? Concerned about the content?Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

View Comments